This PubMed record describes a clinical report titled: A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer. The article is published in Clinical Cancer Research (Clin Cancer Res), cited as 2026 Sep 15;32(18):4016-4025, and carries DOI 10.1158/1078-0432.CCR-26-0874. The PubMed identifier (PMID) is 42347882 and the PubMed Central identifier (PMCID) is PMC13436289.
The study lists multiple authors with primary affiliation to the University of Cincinnati. Lead and contributing authors include Olga Zamulko and Sam Nusbaum (Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati), Andrew Osterburg and Michael Borchers (Division of Pulmonology, Critical Care and Sleep Medicine, University of Cincinnati), and other collaborators from the University of Cincinnati Cancer Center and related departments. Additional contributors are affiliated with the NIH Tech Transfer Office (McKenzie Crist) and St. Elizabeth Healthcare (Muhammad Kashif Riaz). Departments represented include Hematology/Oncology, Pulmonology/Critical Care, Radiation Oncology, Biostatistics and Data Science, and the University cancer center.
This record provides the article identifiers needed to retrieve the full report: PMID 42347882, PMCID PMC13436289, and DOI 10.1158/1078-0432.CCR-26-0874. PubMed includes links to the publisher’s full-text page at the Clinical Cancer Research site and to a free PMC full-text copy.
The PubMed entry classifies this work as a Clinical Trial and lists it under the journal Clinical Cancer Research. The title specifies that the trial is a Phase II feasibility study evaluating the combination of pembrolizumab and metformin in patients with metastatic head and neck cancer.
The provided PubMed page gives comprehensive bibliographic metadata (title, authors, affiliations, journal citation, DOI, PMID, PMCID) and navigation links for figures, references, MeSH terms, and related information. The record also includes links to save or export the citation and to access the full-text sources.
The excerpt of the PubMed page supplied here does not include the study abstract or the trial’s substantive content. Specifically, the following critical elements are not reported in the provided excerpt:
Because these elements are not present in the excerpt, no outcome data, numeric results, or interpretive statements can be summarized from the provided source.
To review the full study methods, results, and authors’ conclusions, consult the full-text versions linked from the PubMed entry. The record links to the Clinical Cancer Research article page at the publisher and to the free PMC full text (PMCID: PMC13436289). Those sources should contain the study abstract, detailed methods (including eligibility and dosing), full results (efficacy and safety), figures and tables, and any supplemental material or conflict-of-interest statements.
Note on source scope
This rewritten summary and the sections above are based solely on the bibliographic and navigation content available in the supplied PubMed record excerpt. The excerpt lacked the trial abstract and outcome data; therefore no specific trial results, numeric outcomes, or recommendations are reported here. Readers seeking trial findings must consult the full text at the publisher or the PMC link provided in the PubMed record.